Mallesons acts on pharma mega deal

Mallesons is acting as Australian and New Zealand legal advisors for Wyeth on its merger with

Lawyers Weekly • 23 March 2009 • Big Law

Mallesons is acting as Australian and New Zealand legal advisors for Wyeth on its merger with Pfizer, announced 26 January 2009. The deal is being touted in the US media as one of the largest pharmaceutical deals in more than a decade.

You’re out of free articles for this month

Username or Email

Password Forgot password?

Keep me signed in on this device.

First Name

Last Name

Mobile

Organisation Type

By becoming a member, I agree to receive information and promotional messages from Lawyers Weekly. I can opt out of these communications at any time. For more information, please visit our Privacy Statement.

Need help signing up? Visit the Help Centre.

Pfizer is the current patent holder of the $12 billion-a-year cholesterol-fighting drug Lipitor. The Lipitor patent is scheduled to expire in 2011, and the company faces a predicted revenue shortfall with anticipated competition in the market from cheaper generic brands.

The merger will bring Wyeth's valuable biotech expertise under the Pfizer umbrella, including products such as Enbrel, a biologic treatment for rheumatoid arthritis. Wyeth and Pfizer have entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $US68 billion ($101 billion). The boards of directors of both companies have approved the merger.

The Mallesons team is being led by partners Katrina Rathie and Sharon Henrick. "The deal is significant for its dazzling $US68 billion-dollar value in this rather depressed market," said Rathie.

"It shows confidence in 'big-pharma' and the consolidation demonstrates the value of intellectual property rights, research and development, innovation pipeline, know how and consumer brands in the all important healthcare market," said Rathie.

VIEW ALL

Wyeth and its animal health division, Fort Dodge, are longstanding corporate clients of Mallesons. Mallesons will work with Wyeth and its New York and London M&A advisors, Simpson Thacher & Bartlett, on the M&A, competition and regulatory aspects of the merger in Australian and New Zealand

We're evolving — and so should your insights. Heads up — Lawyers Weekly is going premium from 1 May for just $5 a month. Stay informed without missing a beat. More information coming soon.

You need to be a member to post comments. Become a member for free today!

Lawyers Weekly - legal news for Australian lawyers

SECTIONS

MORE

Mallesons acts on pharma mega deal

Mallesons is acting as Australian and New Zealand legal advisors for Wyeth on its merger with Pfizer, announced 26 January 2009. The deal is being touted in the US media as one of the largest pharmaceutical deals in more than a decade.

OUR PLATFORMS AND BRANDS

EVENTS AND SUMMITS

PODCASTS

LEARNING AND EDUCATION

MOMENTUM MARKETS NETWORK

LINKS

STAY CONNECTED